Furthermore, by analyzing human patient tissues, we validated that KIAA1199 can be detected at PanIN stage I. Notably, KIAA1199 autoantibody was detected in metastatic pancreatic cancer samples for which the CA19-9 biomarker gave false-negative results (samples C8–C11), indicating the difference in the sensitivity between KIAA1199 and CA19-9. This evidence concerns the gene CEMIP and pancreatic neoplasm.